**Seeking Medical Treatment Abroad: The Best CAR-T Therapy is in China! The First Russian Multiple Myeloma Patient Successfully Achieves Complete Tumor Clearance and CR!**

patient story

Over the five years following his diagnosis of high-risk multiple myeloma, Mr. F endured relentless pain. Despite undergoing various chemotherapy regimens and two transplants, he could never completely escape the nightmare of unpredictable tumor recurrence and progression. Fortunately, by the end of 2023, his condition temporarily stabilized. Accompanied by top hematology experts from Russia, Mr. F traveled to China to receive CAR-T therapy, achieving optimal results with complete tumor eradication and CR (complete remission).

Achieved CR! In February 2024, Mr. F and his family successfully returned to Russia to resume their happy lives.

(Note: To protect patient privacy, pseudonyms are used in the text, and the medical details and treatment process have been slightly modified.)

Mr. F, 63, is the vice principal of a technical college in St. Petersburg, Russia. He has a successful career and a happy family with his wife, one son, and two daughters. In the months leading up to Christmas 2017, Mr. F experienced worsening back pain, with severe pain in the lumbar region. Accompanied by his family, he went to the hospital for a thorough examination. The final diagnosis was multiple myeloma, with osteolytic lesions in more than three areas. The doctor informed Mr. F that, based on the comprehensive assessment of various test results, his myeloma was classified as high-risk (IgG-type, DS-Stage IIIA, ISS-Stage II), making it difficult to treat, prone to relapse, and with a poor prognosis. This devastating news struck suddenly, plunging the entire family into shock and panic. In an interview, Mr. F said, “In Chinese culture, Confucius said, ‘When Heaven is about to place a great responsibility on a man, it always first frustrates his spirit,’ viewing it as a life test. In Western culture, it is seen as God’s punishment, a trial one must endure, with the outcome entirely dependent on how one faces these challenges. I must choose to fight!”

After two days of shock and panic, Mr. F decided to pull himself together and seek the best treatment to fight the tumor. Mr. F and his family consulted many doctors and clinics in Spain, Munich, and Heidelberg. Upon learning that CAR-T therapy had remarkable curative effects on hematologic malignancies, they felt a glimmer of hope, which was soon extinguished. At that time, very few countries offered CAR-T therapy, mostly in developed nations, and the exorbitant cost of nearly a million dollars made it unaffordable even for the well-off Mr. F. To control the disease as quickly as possible, Mr. F underwent traditional CVD therapy in Russia at the beginning of 2018, followed by his first autologous bone marrow transplant, achieving partial remission (PR). Unfortunately, just ten months later, his multiple myeloma relapsed. After switching to a second-line chemotherapy regimen, he underwent a second autologous bone marrow transplant. Despite receiving the most aggressive treatment and enduring life-threatening side effects, tumor lesions persisted in his body, like a ticking time bomb that could explode at any moment. Although maintenance therapy temporarily stabilized the disease, Mr. F and his family remained vigilant. They knew that high-risk myeloma was likely to relapse and progress again in the short term. If the disease worsened once more, they would face a desperate situation with no available treatments.

To completely rid himself of cancer and escape the nightmare of constant relapse and deterioration, five years later, Mr. F and his family once again sought the possibility of a cure through CAR-T therapy worldwide. They conducted extensive research on the CAR-T therapies already on the market and consulted numerous hospitals and experts in Europe, including in India and Israel. To his surprise, despite five years passing, there had been no significant progress in these countries. Almost every expert mentioned that Chinese hospitals had made tremendous advancements in the CAR-T field, surpassing even those in Europe and the United States. Especially for multiple myeloma, on June 30, 2023, China introduced the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and his attending physician immediately contacted Shanghai Jiahui International Hospital in China for an initial remote consultation. Jiahui Hospital, an internationally aligned oncology center with a professional multidisciplinary MDT team, conducted a preliminary evaluation. They concluded that the Iquilence (BCMA CAR-T) treatment plan would be most beneficial and developed a comprehensive plan, addressing all questions and concerns of Mr. F and the Russian experts, ultimately reaching a consensus on the treatment plan.

Professor Li Hua, Director of Oncology at Jiahui International Cancer Center, and his team of Russian hematology experts discussed Mr. F’s treatment plan. Although Mr. F was somewhat aware of China’s medical advancements, he couldn’t imagine that China’s healthcare had surpassed that of the developed Western countries. Therefore, in November 2023, Mr. F’s attending physician, a renowned Russian hematology expert, accompanied him to China to evaluate the feasibility of Chinese CAR-T therapy on-site. Their first stop upon arriving in China was to meet with Jiahui Hospital’s international multidisciplinary treatment team and tour the medical environment that adheres to international nursing standards.

Professor Li Hua, Director of Jiahui International Cancer Center, and his team provided a detailed introduction to the CAR-T treatment plan. Compared to traditional treatments, CAR-T has unique advantages. Firstly, it is a highly personalized treatment that adjusts the patient’s immune system through genetic engineering, providing a more precise response to cancer treatment. Secondly, CAR-T shows significantly higher efficacy in complex cases, which traditional treatments cannot achieve. Iquilence has an overall response rate of nearly 99% and a complete response rate of up to 82.4%. More importantly, fully human CAR-T not only maintains the patient’s quality of life but also provides more durable treatment effects. Additionally, a one-time infusion treatment achieves rapid and effective results, reducing the pain and burden during the treatment process and bringing hope for a cure.+

The second stop for Mr. F and the Russian experts was a visit to the production facility of the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and the Russian experts were impressed to learn that this exceptional therapy was not only entirely developed in-house, but the lentiviral vector was also independently developed. The facility boasts a complete end-to-end development platform and a self-built manufacturing base.

Finally, Mr. F overcame all his concerns and was convinced that China’s fully human BCMA CAR-T solution was world-leading. He decided to undergo treatment in China.

All Tumors Cleared for the First Time, Advanced Myeloma Achieves CR!

In December 2023, just before another Christmas five years after his diagnosis, Mr. F and his family arrived in China, full of hope for a cure, to officially begin his CAR-T journey. At Shanghai Jiahui International Hospital, Mr. F underwent thorough examinations, and after meeting all the requirements, he successfully underwent apheresis, the process of collecting T cells. These cells were then transported back to the factory within 24 hours to create a precisely targeted anti-cancer weapon tailored for Mr. F.

On January 20, 2024, he received lymphodepleting chemotherapy with fludarabine and cyclophosphamide.

On January 25, 2024, the CAR-T cells, carrying the hopes of Mr. F’s entire family, were transported to him by the pharmacy team using professional cold chain logistics. After multiple inspections, unpacking, and reactivation, a small bag of milky white liquid was infused back into Mr. F. The doctors explained that this liquid contained hundreds of billions of “special forces” T cells, which, once in the body, would begin an intense sweep to eradicate the myeloma cells completely.

The infusion process went smoothly. What deeply moved Mr. F and his family was that whenever he felt anxious, the medical team would hold his hand, giving him confidence and strength.

Although a mild cytokine release syndrome (CRS), which is common after CAR-T therapy, occurred post-infusion, the medical team at Jiahui Hospital was very experienced in handling this. With symptomatic treatment, the symptoms improved in about a week. On the 14th day after the infusion, the evaluation showed that the CAR-T cells had expanded effectively in Mr. F’s body, reaching 10^9.

Mr. F said that, unlike the two painful transplant experiences, despite knowing that CAR-T therapy has side effects, the medical team clearly informed him about the reactions he might have at different stages and assured him that the medical staff would address them immediately. As a result, he felt no concerns or fears.

Before the Chinese New Year in 2024, Mr. F was discharged and returned to Russia for further follow-up in his home country. Professor Li Hua said, “The treatment results met our expectations, with significant improvements in key indicators such as serum M protein, free light chains, and disease symptoms. All functional statuses have improved.”

In May 2024, the PET-CT results showed that Mr. F’s lesions had disappeared, and he finally achieved complete remission (CR). This means that after battling multiple myeloma for six years, he has finally won!

A Brighter Future: China Will Become the Best Treatment Destination for Advanced Myeloma Patients!

Now, Mr. F not only resumes his happy and fulfilling life, but he and his wife have also returned to their beloved careers. He currently serves as the General Manager of the UNESCO Mineral Resources Education Center.

Mr. F said, “When I came to China and saw the medical conditions and experienced the best care firsthand, I felt a deep sense of pride for China. It is regrettable that Russia is currently unable to achieve this level of care. However, I will bring my experiences here back to Russia and share them. China’s medical system is world-leading, and choosing to come to China was the right decision!”

In an interview, Mr. F’s wife said, “Although we are past retirement age, we both have very important careers. This CAR-T treatment in China has given us a very precious experience. We have more time to listen to each other’s thoughts, support each other, and get through difficult times together.”

Professor Li Hua, Director of the International Oncology Hospital and Director of the Department of Oncology, said in an interview:

“Clinical research on CAR-T therapy started relatively early in China. Especially since 2020, the number of CAR-T clinical trials in China has far surpassed that in the United States, giving us extensive experience from laboratory research to clinical application.

Moreover, CAR-T treatment in China is more cost-effective, providing patients with a more competitive option.

Most importantly, China has sufficient commercial-quality production capacity. Patients can receive treatment quickly without waiting, which is crucial for those with malignant hematologic diseases who need timely treatment.”

Professor Li Hua, Director of Oncology at Jiahui International Hospital,

The emergence of CAR-T cell therapy has brought new hope to cancer patients worldwide. China’s CAR-T therapy offers outstanding efficacy, good safety, low cost, and rapid preparation advantages. Several international hospitals have opened green channels for overseas patients, making China the best treatment destination for global late-stage multiple myeloma patients!

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago Myeloma

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless.

Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.

In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M. What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!

Reference：

[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.

[2] 2023 IMS. P-290.

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago Leukemia

Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment

Nature Communications | Chinese Medical Team Innovates CAR-T Therapy to Bring New Hope for AML Treatment

AML

In the field of hematological malignancies, the treatment of acute myeloid leukemia (AML) has long been a challenge in the medical community. Particularly for relapsed or refractory patients, the limitations of traditional treatments have increased the urgent need for new therapies. With the advancements in immunotherapy technology, the continuous updating of CAR-T cell therapy has brought new possibilities for the treatment of AML.

Recently, a study titled “CAR-T Cells with C-JUN Overexpression in Acute Myeloid Leukemia: Preclinical Features and Phase I Trial” was published in the journal Nature Communications. This study comprehensively explores the potential optimization mechanisms of CAR-T therapy in AML and was jointly completed by doctors and professors from three top hospitals in China.

During an interview, the Chinese medical team stated that in designing this study, they focused on the major obstacles in CAR-T cell therapy for AML. Although CD33, a highly expressed target, has been extensively explored in multiple studies, safety and efficacy remain challenges. The study found that high expression of CD155 affects the ERK signaling pathway, thereby hindering the effective expansion of CD33. To address this challenge, the research team ultimately selected the overexpression of C-JUN to enhance the exhaustion resistance of CAR-T cells by screening ERK pathway genes. Preliminary results from the clinical trial showed that this overexpressed CD33 CAR-T cell exhibited significant advantages in antitumor function.

Despite the progress, the challenges in CAR-T therapy for AML treatment were also emphasized, including the balance between high efficacy and low toxicity, the expansion of CAR-T cells in myeloid leukemia cells, and the affinity of antibody binding. Subsequent research will focus more on addressing these key issues to enable more patients to benefit from CAR-T therapy.

The Chinese clinical trials revealed some key findings of CAR-T therapy, such as the effectiveness of the bridging transplant strategy and the remarkable efficacy of CD33 CAR-T cells derived from transplant donors. These studies not only provide new insights into the application of CAR-T therapy in AML but also offer references for the optimization of therapies targeting other antigens.

The Chinese medical team will continue to conduct in-depth research around the three core issues of toxicity, expansion, and antigen binding, aiming to overcome challenges and enable more patients to benefit from the breakthrough results of CAR-T cell therapy.

����To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CAR_TCellTherapy #AcuteMyeloidLeukemia #AMLResearch #ImmunotherapyAdvancements #ChineseMedicalInnovation #CancerTreatment #MedicalBreakthrough #NatureCommunications #OncologyResearch #HematologicalMalignancies

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago Myeloma

Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma

### Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

In the treatment of multiple myeloma (MM), how do we find new breakthroughs for patients who have not achieved complete remission (CR) after multiple rounds of chemotherapy? Research by Chinese medical professors has provided an exciting answer: Eque-cel (BCMA CAR-T therapy).

**Patient Background:**

This 58-year-old female patient was initially admitted to the hospital due to numbness and pain in both lower limbs and was eventually diagnosed with multiple myeloma. Despite receiving various treatment regimens, including VRD and SVPD, the results were unsatisfactory, and complete remission was not achieved. Faced with refractory characteristics, the doctors decided to try a more innovative treatment plan—CAR-T cell therapy.

**Treatment Process:**

In September 2023, the patient began peripheral blood mononuclear cell collection, followed by bridging therapy, and in November 2023, she received the Eque-cel infusion. Remarkably, just one month later, the patient achieved hematologic complete remission (CR) with minimal residual disease (MRD) negativity. After six months of follow-up, the patient maintained this excellent therapeutic effect.

**Professor’s Insights:**

Chinese medical professors pointed out that the advent of Eque-cel has brought new hope to refractory MM patients. The drug demonstrated significant efficacy in the FUMANBA-1 study: the overall response rate was as high as 98.9%, with 82.4% achieving complete remission, and 97.8% of patients achieving MRD negativity. The 12-month sustained MRD negativity rate reached 81.7%, and the PFS rate was 85.5%.

This outstanding result proves the significant advantage of Eque-cel in improving the depth of remission for MM patients, bringing hope for long-term survival to many refractory patients.

**Future Outlook:**

As the application and research of Eque-cel continue, we look forward to it providing better treatment options and survival opportunities for more MM patients. This new treatment plan is bringing a ray of hope to this stubborn disease and providing valuable experience for clinical experts worldwide.

**Stay Tuned:**

We will continue to follow the latest developments and research progress of Eque-cel, looking forward to its greater role globally, bringing hope and blessings to more patients.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp:+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CARTTherapy #MedicalBreakthrough #EqueCel #CancerTreatment #MedicalResearch #Hematology #PatientCare #OncologyInnovation #HopeForPatients #BCMA #CART #MM #RRMM

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

2 months ago CAR-T

Expert Perspective: Side Effects and Management of CAR-T Therapy for a Thai Patient

**Expert Perspective: Side Effects and Management of CAR-T Therapy for a Thai Patient**

At the Hematology Department of Shanghai Tongji Hospital, Dr. Li Ping, the chief physician for the elderly Thai patient Ms. P, provided a detailed overview of the patient’s multiple myeloma condition and treatment journey. After experiencing multiple treatments and relapses in Thailand, the patient ultimately chose and trusted CAR-T therapy in China. Dr. Li highlighted that the most common side effect is cytokine release syndrome (CRS), which manifests as fever, hypotension, and difficulty breathing. While most CRS cases are mild to moderate, severe CRS can be life-threatening. She also emphasized that through scientific management, the team’s extensive experience, and the low immunogenicity of the fully human CAR-T product FUCASO, the side effects of CAR-T therapy can be effectively controlled, offering the patient hope for a cure.

We will continue to follow up on this patient’s treatment progress and provide updates.

#CARTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy

• 1
• 2
• 3
• ..
• 6